Cambridge Investment Research Advisors’s MAIA Biotechnology MAIA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,620	Closed	-$15K	–	4122
2026 Q1	$15K	Hold	10,620	–	–	﹤0.01%	3902
2025 Q4	$16K	Buy	+10,620	New	+$13.9K	﹤0.01%	3797

Other funds holding MAIA

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

LCM

Lazari Capital Management Woodland Hills, California $325M AUM 32.83% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $9.98B AUM 26.5% 1-Year Est. Return

CAG

Centerpoint Advisory Group Overland Park, Kansas $158M AUM 26.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Cambridge Investment Research Advisors's MAIA Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of MAIA Biotechnology (MAIA) in Q2 2026, closing a stake of 10,620 shares — an estimated $15K sold.

Cambridge Investment Research Advisors first reported a position in MAIA in Q4 2025 and held it in 2 quarters. The position peaked at $16K in Q4 2025. 5 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

Cambridge Investment Research Advisors reported no remaining MAIA Biotechnology position as of Q2 2026 after selling out during the quarter.
Cambridge Investment Research Advisors sold 10,620 MAIA Biotechnology shares in Q2 2026, an estimated $15K.
Cambridge Investment Research Advisors first reported a position in MAIA Biotechnology in Q4 2025 and held it in 2 quarters.
Cambridge Investment Research Advisors's MAIA Biotechnology position peaked at $16K in Q4 2025.
5 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.